NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Global Health Ltd. (Medanta) recorded a robust 59% compound annual growth rate earnings over FY20-FY24, led by superior execution. We expect a healthy 18% earnings CAGR over FY24-FY26.
Given that Medanta is implementing efforts to further scale up Lucknow/Patna, expand its bed capacity, and add clinical talent, we witness moderate earnings in FY25. However, we expect robust earnings growth from FY26 onwards.
We value Medanta at 33 times 12 months forward enterprise value/Ebitda to arrive at a target price of Rs 1,380. We reiterate Buy on the stock.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
V-Mart Q2 Results Review - Strong SSSG Growth, Lower LimeRoad Losses Drive Beat: Motilal Oswal
Oct 31, 2024
SIS Q2 Results Review - International Business Faces Short-Term Hurdles: Motilal Oswal
Oct 30, 2024
House Of Hiranandani To Invest Rs 12,500 Crore To Develop Multiple Projects In Mumbai Region
Oct 30, 2024
Medanta Gets Target Price Hike As Motilal Oswal Maintains 'Buy'
Sep 09, 2024
POPULAR